How Medicare Part D plans apply prior authorization and step therapy for insulin products under CMS formulary review rules
Scenario
A Medicare beneficiary switches prescription drug plans during open enrollment. She discovers that her new plan covers her insulin, but only with prior authorization. A second insulin on the same formulary requires step therapy. Her prescriber now has to send documentation showing she meets the plan’s clinical criteria.
This situation shows how Medicare Part D plans manage high-cost therapies using utilization controls. Prior authorization and step therapy are allowed under CMS formulary review rules as long as they’re applied consistently and don’t create discriminatory barriers.
How prior authorization works
Part D plans use prior authorization when a medication requires clinical justification before it’s covered. CMS reviews each plan’s formulary submission to confirm the coverage rules are medically appropriate. For insulin, prior authorization usually means the prescriber must verify medical necessity or confirm the patient has tried other therapies. CMS checks that the criteria align with agency standards for clinical soundness and access.
The GAO’s oversight has concentrated mainly on marketplace integrity, but its findings help explain why CMS stresses stronger procedural controls and consumer protections. In 2024, GAO reported that CMS added procedures requiring agents and brokers to get consumers’ consent before certain actions. It fits with CMS’s broader push to keep both plan and agent behavior transparent and compliant.
Step therapy under CMS formulary standards
Step therapy makes beneficiaries try a preferred or lower-cost drug before moving to another in the same class. For insulin, that often means the plan wants a trial of its preferred insulin before a non-preferred version. CMS examines each formulary to ensure these protocols follow clinical standards for safety and effectiveness. Every plan must still allow an exceptions process so prescribers can request coverage without step therapy if it’s medically justified.
What this means for patients and prescribers
Patients should review plan formularies for any prior authorization or step therapy flags before enrolling. Pharmacists and prescribers need to send required forms quickly to avoid coverage delays. CMS oversight tries to keep that balance, ensuring access to essential drugs like insulin while managing Part D costs.
This information is for educational purposes only and should not be considered medical or legal advice.